NEWS

The MPN Research Foundation is pleased to announce the creation of MPN Advocacy International, a new organization founded by former VP of Development Ann Brazeau. MPN Advocacy International will focus on outreach and education for people living with ET, PV and MF. On May 2nd they will host their first event, an educational symposium which will take place in… Read More »MPN ADVOCACY INTERNATIONAL

Today is February 29th – a day that comes every four years. It’s also Rare Disease Day. As you may know, Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis are designated rare diseases. In recognition we wanted to draw your attention to news for the Myeloproliferative Neoplasms community. • The National Organization for Rare Disorders has organized a campaign… Read More »RARE DISEASE DAY 2012

February 25, 2012 One of the biggest challenges facing the MPN Research Foundation in its mission to broaden and accelerate MPN research is raising enough dollars to really make a difference. With NIH and other sources cutting back on funding for medical research in general, our contribution to MPN science and scientists becomes more and… Read More »BIOTECH AND PHARMACEUTICAL JOIN THE FIGHT TO FUND MORE MPN RESEARCH

With funding in part by the MPN Research Foundation, researchers at Mayo Clinic in Arizona have developed a symptom assessment tool for people with Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis. Dr. Ruben Mesa created a way to accurately measure the types and severity of symptoms suffered by patients with one of the myeloproliferative neoplasms (MPNs). Dr. Mesa has been… Read More »RUBEN MESA’S SYMPTOM ASSESSMENT TOOL HELPS PATIENTS WITH MPN

Click here to be directed to the article from Mayo Proceedings Click here to watch the video of Dr. Tefferi describing the study

2011 Benjamin Ebert, MD & Ross L. Levine, MD Harvard Medical School & Memorial Sloan-Kettering Cancer CenterProject Title: “Whole Genome Sequencing to Identify Germline and Somatic Disease Alleles Which Contribute to MPD Pathogenesis“ Two central goals for elucidating the biology of myeloproliferative disease are the characterization of the full complement of somatic mutations that cause MPD,… Read More »SELECTED ABSTRACTS FUNDED BY MPD FOUNDATION 2000-PRESENT, PRESENTED IN CHRONOLOGICAL ORDER

S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF) -S*BIO Explores Partnering Opportunities for Advancement of its Leading JAK2 Program- SINGAPORE, Oct. 25, 2011 – S*BIO Pte Ltd today announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib… Read More »SBIO JAK2 INHIBITOR CLINICAL TRIALS OCTOBER 2011

On Tuesday, September 13, 2011 The Aplastic Anemia & MDS International Foundation and the MPN Research Foundation presented the inaugural MDS/MPN Rounds program at the Doubletree Hotel in downtown Chicago. The Rounds is a case-based symposium with interactive discussion of clinical challenges in the treatment of myeloproliferative neoplasms and myelodysplastic syndromes. This event featured guest speaker Jerry Radich, MD of the… Read More »MDS / MPN ROUNDS 2011

June 2011 A new internet monthly MPN magazine, MPN Forum was pubished Wedsnesday, June 15. The premier issue features Dr. Claire Harrison on rethinking MPNs, a tribute to Karl, plus features, columns and photos from the MPN Community. Check out this great new resource at www.mpnforum.com

June 2011 During ASCO’s annual meeting Incyte announced that it has submitted a New Drug Application (NDA) for Ruxolitinib to the US Food and Drug Administration. They have requested a Priority Review of the application. Ruxolitinib is the first JAK1/JAK2 inhibitor to near commercialization and is now being investigated in other hematology conditions. It is… Read More »INCYTE NEARS THE FINISH LINE FOR FIRST FDA APPROVED TREATMENT FOR MYELOFIBROSIS